Healthcare dealmaking and regulatory momentum picked up as Telix Pharmaceuticals acquired ITM for $1.65 billion and Iambic Therapeutics filed for a US IPO. Grail shares surged 33% on favorable FDA documents, while Beacon Therapeutics advanced its gene therapy toward approval filings. However, Novo Nordisk shares dropped 9% as the company faced intense investor pressure and competition from Eli Lilly over its post-Wegovy growth strategy.
01Company specific
Telix Acquires ITM for $1.6 Billion to Expand Radiopharmaceutical Reach
Telix Pharmaceuticals is acquiring German radiopharmaceutical developer ITM Isotope Technologies Munich for $1.65 billion upfront in a deal that includes up to $700 million in milestone payments. Under the agreement, Telix will also assume more than $300 million of ITM's at closing. Post-, Telix shareholders will own approximately 76.3% of the combined company, while ITM backers will hold the remaining 23.7%. The transaction brings together Telix's cancer diagnostics with ITM's isotope manufacturing infrastructure, which spans more than 65 countries. ITM reported $273 million in sales last year, and the combined entity projects and income topping $1.3 billion this fiscal year. The purchase centers on ITM's lead radiopharmaceutical , ITM-11, which targets the somatostatin receptor for gastroenteropancreatic neuroendocrine tumors. The asset received a complete response letter from the last month due to manufacturing concerns at a third-party facility, though ITM plans to resubmit its application after remediation talks. Telix expects to close the transaction by the end of the year, subject to regulatory conditions.
Novo Nordisk CEO Signals Openness to M&A for Pipeline Expansion
Novo Nordisk is considering and to expand its as competition intensifies in the weight-loss market, cnbc.com reports. CEO Mike Doustdar told CNBC on Tuesday that the company is interested in acquiring external to fill pipeline gaps. The remarks followed a Markets Day on Monday where the company presented a turnaround plan that failed to reassure investors. Novo shares fell 0.75 percent on Tuesday after dropping nearly 8 percent on Monday in their worst trading day since February. Over the past 12 months, Novo shares have declined 34 percent. The company outlined plans to release over five multi-blockbuster drugs by 2030, expecting them to generate more than 150 billion Danish kroner, or $23 billion, in sales by 2035. Meanwhile, U.S. rival Eli Lilly has gained with its treatments, sending Lilly shares up just over 54 percent over the past year.
12-Month Share Price Performance (%)
Novo fell 34 percent while Lilly rose 54 percent over the past year
Beacon Therapeutics Gene Therapy Succeeds in Pivotal XLRP Trial
Beacon Therapeutics succeeded in a pivotal trial for its gene therapy targeting X-linked retinitis pigmentosa, clearing a hurdle where larger competitors like Johnson & Johnson and Biogen stumbled. The phase 2/3 Vista study tested laruparetigene zovaparvovec in 85 men and boys, evaluating two dose levels against a control group over 12 months. No patients in the control group met the responder definition of reading 15 more letters on a low-light eye chart. In contrast, 24.1% of patients in the low-dose group and 31% of patients in the high-dose group achieved the primary endpoint. Beacon plans to initiate a rolling license application to the before the end of the year, alongside seeking approvals in the European Union and the U.K.
FDA Releases Comments Ahead of Advisory Committee Panel Vote on Grail Cancer Test
Shares in Grail surged 33% Monday after the Food and Drug Administration released documents ahead of a Wednesday advisory committee meeting for its Galleri cancer detection test. The blood test is designed to spot multiple cancers early. Grail already offers the diagnostic through its laboratories, but a formal agency approval would pave the way for reimbursement from and other insurers. Advisory panels do not bind the agency, though regulators frequently follow their .
Nvidia-Backed Iambic Therapeutics Files for US IPO
channelnewsasia.com reports that drug developer Iambic Therapeutics filed for a US initial public offering on Monday, seeking to list on the under the symbol IAM. Founded in 2019 as Entos, the company has raised roughly $461.8 million from investors including Nvidia and the Qatar Investment Authority. Its pipeline includes the early-stage candidate IAM1363 for treating solid tumors such as breast cancer, developed using its proprietary platform. The San Diego-based company also maintains partnerships with drugmakers like AbbVie, Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, and Bayer. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are managing the for the offering.
Novo Nordisk Outlines Strategy to Launch Over Five Blockbuster Drugs by 2030
Novo Nordisk shares slid as much as 9% in Monday trading as executives outlined a plan to launch more than five blockbuster drugs by 2030 during a markets day in London. CEO Mike Doustdar told analysts the drugmaker aims to deliver more than 150 billion Danish crowns, equivalent to $23 billion, in pipeline sales by 2035 based purely on internal . The presentation failed to soothe market jitters regarding looming patent expiries for semaglutide in the early 2030s, leaving shares down 4.4% by midday. Competitor Eli Lilly is on track to outsell Wegovy with its rival injection Zepbound by upwards of $7 billion this year. Novo disclosed that staff departures have reached 13,000 following an initial 9,000 layoffs and 4,000 subsequent exits as part of a cost-cutting drive launched last year. Management detailed a multi-year rollout for next-generation obesity treatments, targeting a launch for the CagriSema combination early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028. Out-of-pocket self-pay channels now account for 50% of the entire Wegovy franchise, while direct cash purchases make up 90% of demand for the Wegovy pill.
Novo Nordisk Targets New Blockbuster Drugs to Diversify Beyond Wegovy
Novo Nordisk CEO Mike Doustdar faces pressure on Monday to outline a growth strategy beyond its blockbuster weight-loss drug Wegovy as competition mounts from Eli Lilly. Novo's share price has plunged by more than 70 percent since its peak, while sales of Lilly's rival Zepbound treatment are expected to outpace Wegovy this year by more than $7 billion. In August, Novo raised its sales and operating profit growth targets to between zero and minus 6 percent at constant exchange rates versus 2025, improving from a previous range of minus 4 percent to minus 12 percent. Investors and analysts are urging management to into areas like cardiovascular and rare diseases ahead of patent expiries for semaglutide, the active ingredient in Wegovy and Ozempic, in the early 2030s. The company's late-stage pipeline has thinned following trial setbacks for experimental heart drug ziltivekimab and next-generation obesity treatment CagriSema.
Strong clinical results and M&A activity are driving targeted sector gains, even as mega-cap pharmaceutical leaders face steep valuation haircuts. Whether new pipeline acquisitions can offset looming patent losses for top drugmakers before rivals capture market share stays unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.